Before paying NativeMed, a prospective patient has several different questions to answer: What medication is being offered? Who decides whether it is appropriate? What is charged today? And who handles a problem after shipment? NativeMed’s three consulted pages provide useful starting points, including specific prices, a questionnaire-based assessment and partner-pharmacy fulfillment. They do not provide a complete enrollment agreement or enough detail to trace every clinical and financial responsibility.
This documentary review examines NativeMed through those patient questions rather than treating a low advertised monthly figure as the whole offer. The public pages, consulted October 19, 2026, describe compounded injectable semaglutide and tirzepatide—not FDA-approved versions of those products. They also distinguish NativeMed’s access-facilitation role from prescribing and dispensing. Understanding those distinctions, and getting unresolved terms in writing, is more useful than assuming the checkout experience explains the entire care arrangement.
At a glance
- Documented medications
- NativeMed advertises compounded injectable semaglutide and compounded injectable tirzepatide; semaglutide is promoted from $149 per month.
- Published payment choices need clarification
- Semaglutide displays $149 per month with $447 upfront and a separate $179-per-month block with a $159 first month. Tirzepatide displays $183 per month with $549 upfront and a separate $259-per-month block with a $199 first month. The captured plan labels do not unambiguously identify every selection.
- Self-pay arrangement
- NativeMed says it does not bill insurance, charges no membership fees and offers the same price at any dose. HSA and FSA cards may be accepted where eligible.Sources: [5]
- Prescription and fulfillment
- A licensed healthcare provider reviews the questionnaire and determines appropriateness. If prescribed, the prescription goes to a partner pharmacy for fulfillment and direct shipment.Sources: [5]
- Cancellation statement
- NativeMed says there are no long-term contracts or cancellation fees and that patients are responsible only for medication already shipped. The consulted documentation does not explain refunds of prepaid balances.Sources: [5]
Who would actually be responsible for your care?
NativeMed describes itself as facilitating access to compounded medication when a licensed healthcare provider prescribes it and a licensed compounding pharmacy dispenses it. It expressly says it does not manufacture medications, practice medicine or decide whether a particular medication is appropriate for an individual. That makes the identities of the prescribing practice and dispensing pharmacy important enrollment questions, not minor administrative details. The consulted pages do not identify the operating legal entity, contracting clinical entity, individual clinicians or specific partner pharmacies.
The site advertises virtual consultations with licensed providers and describes the service as “100% online.” A tirzepatide-page passage also mentions completing a short questionnaire or an in-person appointment. The documentation does not explain where that in-person option exists or how it fits the online pathway. Ask which consultation format applies to your application, who conducts it and whether any separate appointment is required before a prescribing decision.
Geography is another unresolved part of the arrangement: the consulted pages do not establish a state-by-state service list or verified nationwide availability. References to licensed U.S. professionals and pharmacies are NativeMed’s statements, not independent credential checks. Before submitting payment, request confirmation that the clinical practice and pharmacy can serve your state. Our guide to what a program should explain before enrollment provides a framework for organizing those answers.
What medicine is the offer actually for?
NativeMed’s weight-management product pages identify compounded semaglutide and compounded tirzepatide, both injectable. The tirzepatide page describes a dual-action GLP-1/GIP medication. Those product descriptions should stay attached to any price comparison: an offer for a compounded injectable is not interchangeable with an offer for an FDA-approved branded product or another route of administration. Ask for the exact prescribed preparation, presentation and dispensing pharmacy rather than relying solely on the ingredient name in an advertisement.
FDA explains that compounded preparations are not FDA approved and do not undergo its premarket review for safety, effectiveness and quality. That distinction does not, by itself, establish clinical inequivalence or prove anything about NativeMed’s individual products. FDA recommends compounded drugs for patients whose medical needs cannot be met by an FDA-approved drug, with a prescription and a state-licensed pharmacy. A useful consultation question is how that recommendation applies to the particular preparation being considered for you.
The homepage also advertises NAD+ injections, including a starting-at-$160 block and another promotion from $160 per month, plus an unnamed growth hormone–stimulating peptide from $149 per month. These are separate offers, not documented inclusions in the GLP-1 prices. The NAD+ promotion includes an FDA-related disclaimer. Its energy and longevity messaging should not be treated as independent clinical evidence. Keep the discussion focused on the specific product you are considering and its documented purpose.
Which price would appear on your first charge?
NativeMed publishes real dollar amounts, but the relationship between its plan labels and price blocks needs confirmation. The semaglutide page displays $149 per month with $447 paid upfront, alongside monthly and three-month labels. A different block shows $179 per month and a $159 first month. Tirzepatide similarly displays $183 per month with $549 upfront, plus another block showing $259 per month and a $199 first month. The captured text does not preserve every visual plan selection clearly enough to assign all terms confidently.
These figures should not be flattened into one universal monthly price or a mandatory upfront requirement for every customer. They show different payment presentations, including introductory amounts and upfront collection. A three-month plan label alone does not establish the amount of medication supplied or a minimum contractual commitment. Before paying, ask NativeMed to identify the exact plan, the amount collected immediately, the period covered and the amount and timing of the next charge.
The homepage also promotes a limited-time first-order discount through a signup form, without quantifying it in that block. There is no basis here to assume it stacks with either advertised first-month price. Request a final written quote showing which promotion applies and whether it changes later charges. For a structured checklist, use these price questions beyond the monthly headline, especially when comparing an introductory payment with an upfront package.
| Offer | Published payment language | Confirm before paying |
|---|---|---|
| Compounded semaglutide, upfront block | $149 per month; $447 paid upfront | Selected plan, covered period and quantity supplied |
| Compounded semaglutide, introductory block | $179 per month; first month $159 | Next charge date and subsequent billing terms |
| Compounded tirzepatide, upfront block | $183 per month; $549 paid upfront | Selected plan and treatment of unused prepaid funds |
| Compounded tirzepatide, introductory block | $259 per month; first month $199 | Promotion eligibility and subsequent billing terms |
What does self-pay include—and what remains separate?
NativeMed says it does not bill insurance and instead offers self-pay pricing with flexible payment options. It also says HSA and FSA cards may be accepted where eligible. That conditional wording is not a promise that every card or expense qualifies, and “flexible” does not identify a financing agreement, installment schedule or credit terms. Ask which payment methods are available for your selected plan rather than assuming the monthly figure means monthly collection.
The homepage advertises no membership fees and the same price at any dose. The semaglutide page adds free shipping if prescribed and “no hidden fees.” These are useful commercial representations, but the consulted pages do not itemize every service included in each price. They do not resolve whether outside laboratory testing, additional consultations or other third-party costs could be separate. A written list of inclusions would make the advertised price easier to compare with another program’s offer.
The practical question is not merely whether NativeMed has a membership charge; it is what you receive for the payment you authorize. Ask whether the initial clinical review, prescription processing, follow-up encounters and supplies are included in that specific plan. Also ask what happens financially if the reviewing clinician does not prescribe. The public documentation describes an appropriateness review, but it does not establish a complete payment-and-refund process for an unsuccessful application.
What happens between the questionnaire and a prescription?
NativeMed’s documented starting point is a patient questionnaire. A licensed healthcare provider then reviews the information and determines whether treatment is medically appropriate. The site says treatment decisions involve medical history, eligibility and treatment goals; the semaglutide page likewise conditions prescribing on clinical appropriateness for the individual. This is a conditional assessment pathway, not a guaranteed prescription. NativeMed’s “approval in 5 minutes” promotion does not explain exactly what approval means or replace the stated clinical review.
The consulted pages do not establish a minimum age, complete eligibility criteria, required tests or clinical exclusion rules. NativeMed’s BMI calculator is explicitly informational rather than diagnostic. It therefore cannot establish acceptance into the program. Ask what information the clinician needs, whether records or laboratory results are required, and how questions can be addressed before a decision. Those answers matter more than interpreting the calculator or a brief promotional timeline as an admission standard.
For preparation, NIDDK advises discussing medicines, supplements, allergies and pregnancy plans with the treating clinician. NativeMed’s tirzepatide page also asks patients to disclose medications and supplements. NIDDK describes medication selection as a discussion of benefits, side effects, health conditions, other medicines, family history and costs. Bring those topics to the consultation rather than looking to a review for individualized eligibility or dosing advice. The public pages cannot substitute for that patient-specific exchange.
When would medication arrive, and who handles a delivery problem?
If medication is prescribed, NativeMed says the prescription goes to a partner pharmacy for fulfillment and direct shipment. Its semaglutide page describes licensed U.S. compounding pharmacies, without naming them in the consulted material. The homepage FAQ says orders typically ship within one to three business days after the dispensing pharmacy has approved and processed the prescription. That is a dispatch estimate after a specified processing stage—not an arrival promise measured from the time you complete the questionnaire.
A separate homepage block advertises delivery in three days or less and free overnight shipping with an asterisk. The tirzepatide page says approved prescriptions ship free and discreetly within a few days. These statements have different starting points and meanings, and the consulted documentation does not explain the overnight-shipping asterisk, carrier or tracking process. Ask for the applicable timeline for your address, the pharmacy’s processing expectations and the contact route for a delayed or damaged package.
The pages also do not describe the cold-chain process or a replacement policy for temperature concerns. FDA explicitly advises not using an injectable GLP-1 drug that arrives warm or insufficiently refrigerated, and contacting the provider or dispensing pharmacy. Establish those contact details before shipment rather than waiting for a problem. Our guide to shipping and delivery questions can help separate processing, dispatch, transit and problem-resolution responsibilities.
What does “24/7 provider support” mean in practice?
NativeMed advertises “24/7 Provider Support,” and its FAQ promises ongoing support throughout the program. Neither statement specifies a routine appointment schedule, communication channel or response-time commitment. Around-the-clock availability could describe access to a messaging system rather than an immediate clinical response; the consulted pages do not resolve that distinction. Ask who receives messages, which questions reach the prescribing clinician, what response time is expected and whether follow-up visits are included in the selected price.
NIDDK describes follow-up as addressing treatment response and tolerability, not simply continuing payments. FDA has also received reports of compounded-medication measurement or administration errors, including some associated with hospitalization. Those reports do not establish a NativeMed-specific event rate. They do make the instruction pathway important: ask who explains the prescribed preparation, how to obtain clarification from the prescriber or pharmacist and how uncertainties are resolved without relying on calculations from an online review.
There is also a distinction between access claims and clinical outcome evidence. The consulted NativeMed pages do not establish independently measured outcomes for its program. Published drug trials do not establish the results of this provider or its compounded preparations. Support questions should therefore focus on observable service commitments: planned reviews, access to the care team and how concerns are handled. Our questions about support after the first prescription offer a practical way to request those details.
How would you stop—and what happens to prepaid money?
NativeMed’s FAQ says there are no long-term contracts or cancellation fees and that patients are responsible only for medication already shipped. That is a meaningful stated boundary, but it is not a complete cancellation policy. The consulted material does not establish automatic-renewal terms, a cancellation submission channel or a minimum notice deadline. Ask how cancellation is acknowledged and how to prevent another order from moving into fulfillment while the request is being handled.
The upfront price blocks create a separate question: how is an unused prepaid balance handled if treatment or participation ends? Cancellation without a fee does not automatically mean a refund, and the reference to medication already shipped does not explain how a prepaid package is reconciled. The contents of linked refund policies and full terms were not available within this review’s documentation. Request the applicable agreement and refund terms before authorizing an upfront charge.
Finally, financial cancellation and clinical follow-up are different responsibilities. NIDDK notes that treatment duration depends on response and side effects, and that obesity may require long-term care. NativeMed’s lack of a stated long-term contract should not be read as a prediction about treatment duration or maintained results after stopping. Ask both how the account ends and how clinical questions are addressed during a transition, without assuming that one cancellation message resolves both.
Questions & answers
Is NativeMed itself the prescribing medical practice?
NativeMed says it facilitates access and does not practice medicine or determine medication appropriateness. It assigns those decisions to licensed healthcare providers and dispensing to partner pharmacies. The consulted pages do not identify the specific clinical entity or clinicians. Ask for the practice name, prescriber credentials and applicable patient agreement before enrolling.
Is semaglutide always $149 per month?
No universal $149 monthly arrangement is established. NativeMed advertises compounded injectable semaglutide from $149 per month and displays $447 upfront in one price block. Another shows $179 per month with a $159 first month. Because the captured plan labels are ambiguous, confirm the selected payment schedule and later charges rather than assuming every patient receives the lowest headline amount.
Does NativeMed accept insurance or HSA/FSA cards?
NativeMed says it does not bill insurance and uses self-pay pricing. It says HSA and FSA cards may be accepted where eligible, which is conditional rather than guaranteed. The site mentions flexible payment options but does not document their full structure. Confirm the accepted payment method and exact charge before relying on either card eligibility or an installment arrangement.
Does five-minute approval mean medication arrives immediately?
No. NativeMed’s five-minute approval promotion is distinct from clinical review, pharmacy processing and shipment. Its FAQ says orders typically ship one to three business days after pharmacy approval and processing. Separate delivery and overnight-shipping promotions do not establish a single guaranteed application-to-arrival timeline. Ask which estimate applies to your order and location.
Can I cancel an upfront plan and receive the unused balance?
The consulted documentation does not settle that question. NativeMed says there are no long-term contracts or cancellation fees and that patients are responsible only for medication already shipped. It also displays upfront payment blocks. Those statements do not explain prepaid-balance refunds, renewal timing or the cancellation procedure. Obtain those terms in writing before choosing an upfront offer.
What should I do if an injectable delivery arrives warm?
FDA advises not using an injectable GLP-1 drug that arrives warm or with insufficient refrigeration and contacting the provider or dispensing pharmacy. NativeMed’s consulted pages do not explain its cold-chain incident or replacement procedure. Request the pharmacy’s contact information and the delivery-problem process before shipment so the appropriate team can address a concern promptly.
Our assessment
NativeMed documents more than a medication headline: it publishes specific compounded-injectable prices, describes clinician review and pharmacy fulfillment, and states no membership or cancellation fees. Those details provide a useful basis for questions. The unresolved issues are consequential, however: plan-to-price mapping, the identities of care partners, state availability, follow-up commitments and prepaid-balance treatment. A practical next step is to request one written account of the selected medication, first and later charges, responsible clinical practice, pharmacy, support process and exit terms. That would turn the advertised offer into something a prospective patient can evaluate without assuming that convenience claims supply the missing contractual or clinical details.
This opens the reviewed business’s website. The link is not a prescription or endorsement. Commercial relationships.
Sources & documentation
Public materials consulted October 19, 2026. Provider statements are attributed claims, not independently verified clinical outcomes. Terms can change; obtain a current written quote.
- FDA concerns with unapproved GLP-1 drugs used for weight loss ↗
- NIDDK: prescription medications for overweight and obesity ↗
- Wilding et al. (2021): STEP 1 semaglutide trial ↗
- Jastreboff et al. (2022): SURMOUNT-1 tirzepatide trial ↗
- NativeMed — official website ↗
- NativeMed — products/tirzepatide ↗
- NativeMed — products/semaglutide ↗